Sangamo Therapeutics (SGMOQ) Shares Outstanding (2010 - 2025)

Sangamo Therapeutics has reported Shares Outstanding (Entity) for 16 years, with the latest figure at $280.2 million in Q4 2025.

• On a quarterly basis, Shares Outstanding (Entity) rose 31.65% year-over-year to $280.2 million in Q4 2025; TTM through Dec 2025 was $280.2 million, a 31.65% increase from a year earlier, with the FY2025 full-year figure at $280.2 million, up 31.65% from the prior year.
• Shares Outstanding (Entity) was $280.2 million for Q4 2025 at Sangamo Therapeutics, down from $336.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $336.5 million in Q3 2025, with the low at $143.9 million in Q1 2021.
• Average Shares Outstanding (Entity) over 5 years is $195.4 million, with a median of $177.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) climbed 1.95% in 2022, then surged 61.27% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $145.9 million in 2021, then gained by 14.3% to $166.8 million in 2022, then grew by 6.8% to $178.1 million in 2023, then grew by 19.48% to $212.8 million in 2024, then soared by 31.65% to $280.2 million in 2025.
• The last three Shares Outstanding (Entity) figures came in at $280.2 million (Q4 2025), $336.5 million (Q3 2025), and $301.7 million (Q2 2025), per Business Quant data.